FDA Perspective on the Regulation of AI in Health Care and Biomedicine
This Special Communication examines advances in the use of artificial intelligence in health care and biomedicine and how regulatory entities like the US Food and Drug Administration must evaluate how artificial intelligence operates within these sectors to develop appropriate regulatory frameworks.